Canakinumab Novartis (canakinumab)
- Region
- 🇪🇺 EU
- Active substance
- canakinumab
- Company
- Novartis Europharm Limited
- Status
- Application withdrawn
- Therapeutic area
- Acute Coronary Syndrome; Myocardial Infarction; Stroke
- Application
- EMEA/H/C/004754
- ATC
- L04AC08
- Official record
- www.ema.europa.eu
Indication
Prevention of major cardiovascular events
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Ilaris Authorised · Novartis Europharm Limited
Follow Canakinumab Novartis
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.